Aytu BioPharma

Aytu Bio Pharma

Pharmaceuticals, 373 Inverness Parkway, Denver, Colorado, 80112, United States, 51-200 Employees

aytubio.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 72********

Who is AYTU BIOPHARMA

Aytu BioPharma (NASDAQ: AYTU) is a dynamic specialty pharmaceutical company with a growing commercial portfolio of prescription medicines addressing complex conditions, with a focus on AD...

Read More

map

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AYTU BIOPHARMA

Aytu BioPharma Org Chart and Mapping

Employees

Kunj Samani

Engineering and Maintenance Manager

Jarrett Disbrow

Executive Vice President, Corporate Development

Sashikala Somasundaram

Research and Development Scientist

Madison Pascoe

Accounts Payable Specialist

Jaquelin Mendoza

Pharmaceutical Production Technician

Sara Pilgrim

Pharmaceutical Sales Representative

Nicole Derksen

Senior Territory Sales Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Aytu BioPharma

Answer: Aytu BioPharma's headquarters are located at 373 Inverness Parkway, Denver, Colorado, 80112, United States

Answer: Aytu BioPharma's phone number is 72********

Answer: Aytu BioPharma's official website is https://aytubio.com

Answer: Aytu BioPharma's revenue is $100 Million to $250 Million

Answer: Aytu BioPharma's SIC: 2834

Answer: Aytu BioPharma's NAICS: 325412

Answer: Aytu BioPharma has 51-200 employees

Answer: Aytu BioPharma is in Pharmaceuticals

Answer: Aytu BioPharma contact info: Phone number: 72******** Website: https://aytubio.com

Answer: Aytu BioPharma (NASDAQ: AYTU) is a dynamic specialty pharmaceutical company with a growing commercial portfolio of prescription medicines addressing complex conditions, with a focus on ADHD and other common conditions. Our evolution has been driven by strategic in-licensing, acquisition-based transactions and organic product growth. As we continue on this trajectory, we continue to evaluate novel therapeutics to in-license or acquire.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access